NCT02174887View on ClinicalTrials.gov

Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

Nab-paclitaxel + Gemcitabine

"Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days~The patients will receive 2 cycles of treatment every 28 days:"

Trial Locations (1)

13009

Institut Paoli-Calmettes, Marseille

All Listed Sponsors
lead

Institut Paoli-Calmettes

OTHER

NCT02174887 - Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter